Caspofungin--a new therapeutic option for oropharyngeal candidiasis.
Patients with AIDS are often severely immunocompromised. These patients commonly develop opportunistic infections such as oropharyngeal candidiasis whose treatment may prove to be difficult. Caspofungin belongs to a new class of antifungal agents that have a different mode of action to azoles and polyenes. This new agent is the first inhibitor of fungal glucan synthesis to receive approval for the treatment of mucosal and invasive candidiasis and invasive aspergillosis. Caspofungin is well-tolerated and represents a substantial improvement over existing therapeutic options for patients prone to azole-resistant candida infection or who cannot tolerate amphotericin B.
J
J
Garbino
D000935:Antifungal Agents / Q000627:therapeutic use*; D002177:Candidiasis / Q000188:drug therapy*; D002180:Candidiasis, Oral / Q000188:drug therapy*; D000077336:Caspofungin; D054714:Echinocandins; D006801:Humans; D055666:Lipopeptides; D010455:Peptides / Q000627:therapeutic use*; D010456:Peptides, Cyclic; D010608:Pharyngeal Diseases / Q000188:drug therapy*
D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; D010455:Peptides; D010456:Peptides, Cyclic; D000077336:Caspofungin